Technology | Catheters | January 07, 2016

Roxwood Medical Proceeds with Full U.S. Launch of MicroCross Catheter

More than 500 patients treated successfully in coronary and peripheral vasculatures in limited release

Roxwood Medical, MicroCross Catheter, full U.S. launch

Image courtesy of Roxwood Medical

January 7, 2016 — Roxwood Medical Inc. reported that more than 500 patients have been successfully treated as part of the initial limited release of its MicroCross Catheter, the latest addition to Roxwood Medical’s expanding product line. The MicroCross Catheter is U.S. Food and Drug Administration (FDA)-cleared and offered in two sizes (Micro14 and Micro18) for use in the coronary and peripheral vasculatures, providing enhanced guidewire support through challenging and tortuous anatomy.

Compatible with Roxwood Medical’s CenterCross Catheter, MicroCross is comprised of an ultra-low profile shaft featuring variable pitch braid technology and a state-of-the-art lubricious coating. These features allow for enhanced trackability and guidewire support while navigating tortuous regions of the coronary and peripheral vasculature.

“I have been impressed with the performance of the catheter in my early experience,” stated Jeff Moses, M.D., of Columbia University Medical Center. “The increased complexity of our treatment approach for coronary occlusions puts a lot of demand on the tools we use. The low profile and trackability of Micro14 provides an exciting new tool for us to access and cross these highly complex lesions.”

“Since first using the Micro14 and Micro18, we continue to be struck by the performance of the catheters, which have quickly become an essential part of our Critical Limb Ischemia toolkit,” said Fadi Saab, M.D., of Metro Heart Hospital, Wyoming, Mich. “These are now our frontline tools to navigate across difficult lower extremity blockages, leading to effective treatment of our patients’ severe peripheral arterial disease (PAD).”

For more information:

Related Content

DABRA Excimer Laser System Demonstrates Success in Treating PAD
News | Cath Lab | February 27, 2019
Ra Medical Systems Inc. announced a 98 percent success rate in the results from a 52-patient study using the company’s...
Edwards Lifesciences Recalls Swan-Ganz hemodynamic catheters.
Feature | Cath Lab | February 06, 2019
Edwards Lifesciences is recalling its 131F7, 131F7J, 131F7P, 131VF7P, 151F7 Swan-Ganz Thermodilution Catheters manufa
Scientists Discover New Heart Attack Repair Pathway

A macrophage immune cell, with a dead cell (pink) that has been eaten, and a mitochondrion (green) between the dead cell and the nucleus. The study’s findings indicate that what the macrophage eats is taken up by the mitochondrion, which in turn communicates with the nucleus to activate the macrophage to promote tissue repair. Image courtesy of Northwestern Medicine.

News | Cath Lab | January 30, 2019
Northwestern Medicine scientists have discovered a novel signaling pathway that promotes healing after a heart attack....
Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
National Academy of Engineering, Ohio University Award 2019 Russ Prize
News | Cath Lab | January 03, 2019
Ohio University and the National Academy of Engineering announced the 2019 Fritz J. and Dolores H. Russ Prize will be...
Videos | Cath Lab | January 03, 2019
This is a walk through inside one of the cardiac hybrid cath labs at the...
Videos | Cath Lab | January 03, 2019
This is the newest cardiac cath lab at the ...
Study Finds Effective Treatment for Coronary Slow Flow
News | Cath Lab | December 27, 2018
Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if...
Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Overlay Init